FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to neuropathology and psychiatry, and can be used to stimulate hippocampal neurogenesis in depression-like conditions in mammals. Method includes sampling of mature peripheral immune cells in a mammal in a depressive state, cells undergo in vitro exposures with caffeine or pharmacologically active caffeine salts at active concentrations of 100–500 mcg per 15 × 106 cells for 10–25 minutes. Then, the cells are washed from caffeine preparation and injected into the bloodstream of the mammal in a depressive state.
EFFECT: use of invention allows to stimulate neurogenesis in the hippocampus without directly introducing caffeine into the body.
3 cl, 3 dwg, 5 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR BRAIN CELL REGENERATION WITH RECOVERY OF ITS FUNCTIONS | 2023 |
|
RU2816789C1 |
| METHOD FOR REDUCING ALCOHOLIC MOTIVATION IN MICE | 2020 |
|
RU2744411C1 |
| IMMUNOMODULATOR | 2020 |
|
RU2747986C1 |
| IMMUNOMODULATOR | 2019 |
|
RU2702114C1 |
| RECOMBINANT PLASMID DNA AAV SYNH1-2_SHRNA FREUD-1, PROVIDING SYNTHESIS OF SHPHK, SUPPRESSING EXPRESSION OF GENE CODING SELECTIVE SILENSER 5-HT1A OF RECEPTOR FREUD-1, IN BRAINS OF MAMMALS | 2019 |
|
RU2726764C1 |
| METHOD FOR TREATMENT OF NEUROPATHIC PAIN | 2021 |
|
RU2780139C1 |
| IMMUNOMODULATOR | 2018 |
|
RU2691143C1 |
| AGENT STIMULATING NEUROGENESIS IN ISCHEMIC CEREBRAL INJURIES | 2015 |
|
RU2585094C1 |
| TARGETED NON-INVASIVE TRANSPLANTATION INTO BRAIN OF FUNCTIONALLY ACTIVE MITOCHONDRIA FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2744453C2 |
| AGENT FOR STIMULATING PROLIFERATIVE ACTIVITY OF BONE MARROW CELLS | 2023 |
|
RU2811901C1 |
